By Colin Kellaher


Pfizer Inc. on Thursday said a Phase 3 study combining its breast-cancer drug Talzenna with its prostate-cancer drug Xtandi showed a 37% reduction in the risk of disease progression or death in men with metastatic castration-resistant prostate cancer compared with Xtandi plus placebo.

The New York drugmaker also said the U.S. Food and Drug Administration granted priority review to its application seeking approval of the combination for the treatment of men with the condition.

The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period.

Pfizer, which is conducting a Phase 3 study of the combination in men with metastatic castration-sensitive prostate cancer, said it expects a decision from the agency sometime this year.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

02-16-23 1038ET